Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

January 3, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

May 31, 2026

Conditions
Obesity Control
Interventions
DRUG

HDM1702

Initiate at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg per week) aiming at reaching the maintenance dose of 2.4 mg at week 16.

DRUG

Wegovy ®

Initiate at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg per week) aiming at reaching the maintenance dose of 2.4 mg at week 16.

Trial Locations (1)

Unknown

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY